Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice to see EDTXF is attending the JP Morgan show is January. This is by INVITE only. What up with this underachiever??
A better sign would be an invite to the JP Morgan show in January. Here is hoping and yes June and the cancer angle has been brewing now for 3 years or more? Likely to be the next catalyst...here is hoping!
Poster Paulness part of CTSO pump group. I think EDTXF will achieve a FDA approval years before CTSO. I liked CTSO, but have noticed a complete unwillingness for them to even discuss Spectral on their IHIUB page. Something strange is afoot here. I'm starting a position on EDTXF. You need to go to the EDT forum up in Canada to get info and news on this company. Try Spectrals website to start.
Poster Paulness part of CTSO pump group. I think EDTXF will achieve a FDA approval years before CTSO. I liked CTSO, but have noticed a complete unwillingness for them to even discuss Spectral on their IHIUB page. Something strange is afoot here. I'm starting a position on EDTXF. You need to go to the EDT forum up in Canada to get info and news on this company. Try Spectrals website to start.
I learned too late about the importance of 28 day mortality in critical care devices. I lost a good bit of money on my first foray into this leader in the space. In order to prosper and gain the $80 to $100 share price levels as often promoted here by team Pearsy, we'll need 28 day mortality numbers in some way,shape or form. Nuff said, the nephrologist agrees and he doesn't babysit public stock forums for a living, he saves lives! nuff said II !
Strong point, but what about the idea of a sepsis trial and FDA approval for our company? How are we going to advance our product forward with NOTHING that addresses 28 day mortality? Afterall Pearsy, this is in fact the Holy Grail in the world of critical care medicine, just ask anyone on our scientific advisory board.
Refresh II moving along nicely. I do wish these guys would run a sepsis trial here in the US. Given the XL, the experience of 50,000 patients and the superior product offering, how can Spectral run a 450 person phase 3 trial in 55 centers with full 28 day mortality data and CTSO not even include 28 day and not even run their trial in the sepsis search for answers? I'm calling a tactical error here as our competitor has positioned themselves to take the lead in the most important US market. Given we all agree and think we know our technology is far superior, why in the name of sepsis are we not front and center in the clinical arena as the leaders in this massive unmet need ? We have the cash, let's get a small sepsis trial done asap to firmly establish our leadership in this most important race. F-inlaw's nephrologist friend asked similar questions over tacos last night and did ask for a rolaid...not sure if it was question or spice related so I didn't push my questioning.
Hey Catter,
I was thinking the exact same thing all about the XL Sorb and it's ability to eat Spectral's cold, stale lunch! The best part of this is the fact that Spectral has taken their Japanese leased technology all the way through a completed US FDA phase III AND gained a compassionate care approval....stay with me Catter....so if this is the case then the Sorb XL is an absolute LOCK to garner approval because we remove endotoxin and add a complete buffet of other toxin removals! I say any advancement from Spectral is simply setting the table for Sorb XL domination! You heard it here first!!!
Nice try Sport! The market has spoken and CTSO is valued in the area of 10 multiples greater then that of EDTXF. Nothing competes with the beads and the sales here speak volume...millions of volumes. Let's just hope this little upstart can run a few patients thru the que! Any hint of success from them will bode well for CTSO moving forward. As a matter of fact, we might take them out with a mere 5M share issuance...something to consider for certain. I might bring this idea up over tacos...will share accordingly!
Great news for our filtration space! Two weeks ago it was AEMD getting breakthrough status with the FDA. Today Spectral Medical announced they too are closing in on their confirmatory phase 4 trial to prove up their treatment for Sepsis! This all bodes well for us here at CTSO, having these little nano-caps cut ice for the Big Boy is especially nice of them. I'm having tacos with my F-inlaw's nephrologist friend tonight. If the mode is right I might bring up CTSO again and get his his take which I'm sure to share here with the guys! GLTA!!!
Are you calling me a condom you ignorant sob?
I won a creative writing award in college and then it just blossomed from their. The humor part is thanks to years of the Stooges and Abbott and Costello. I blog in and around the valley and sometimes do stand up when I'm posted upstate. If you want more material I can send it to you with an attached e-mail. A pleasure to serve you, I would like to see some more kibitzing ( light chit chat, talk amongst your elves ) on the value of the BIG 3. I've often dreamt of moving between the three with an active trading program to hit the highs and lows as the filtration cycle absorbs the bad and spits out the good. Let's all join and hold one another high...it's the strength in all of us collectively that brings the market to it's knees allows for a united movement forward. Cheers to 52 week highs and a collective bead-stalk that would bring a smile to a desperate young Jack.
Here are the values of the Big 3 filtration plays;
AEMD is valued at 24 million
EDTXF is valued at 40 million
and the leader is valued at......
CTSO is valued at 287 million or a solid 7 times the #2 horse or 11 times the #3 horse.
nuff said
OH no he explained the after hours activity as cake frosting...I'm not sure what it means but there appears to be a few bakers present
I'm also surprised the many posters don't kibitz over the other players and their advancement or lack there of....I would like to buy AEMD and hoped some of the designated intelguys could shed light...instead i haear about Joyce's removal...does this matter? AEMD has made major FDA strides and is valued at a fraction CTSO..what gives??
Aethlon, Spectral and Cytosorbent ..... can someone provide a quick pro and con on each of these filtration companys? Allow me to start and give my quick opinion ... I'll rank them with CTSO clearly in the #1 hole
1) CTSO = the leader with growing sales and the newest technology. The beads are very versatile and can treat almost anything. Great case studies but a little light in the loafers on randomized control trials and hard data on efficacy. REFRESH II should help, but like to see a 28 day mortality thrown into the secondary endpoint convo
2) EDTXF = Old technology and little in the way of sales. Perhaps the biggest stable of scientific backing and a complimentary diagnostic tool to help decide on treatment ...when, where and how much. Their product, Toraymyxin did receive a FDA compassionate care approval during their recently completed phase 3 trial here in the US. Likely need more trial work and waiting on an answer from the FDA. EDTXF trades OTC and does not share any company news through their trading symbol..a wait and sea story...don't buy the boat just yet
3) AEMD = perhaps the most interesting of the bunch with excellent insider backing and a niche product for infectious disease. Was an option during Ebola and could surprise with recent FDA fastrack designation. Perhaps worthy of the #2 hole, but the enormous usage on Spectral's Toraymyxin allows them to occupy the #2 hole ...for now.
Place your bets and have a super weekend
Much better, a nice meal at Mortons with a decent bottle of wine. The real value is the increase in company value of about 60 MILLION. I've had nice steak and suggested it was a million dollar meal, but never one worth 60 MILLION. Great fodder for weekend posting though.
Surprised at the level of investor intelligence here. Did you read the abstract? You do understand what an abstract is? You somehow think this paper allowed for a 50 MILLION increase in the company value by way of an $11/share trade for the value of a quick dinner at Sonic with milkshakes all round? I'm shocked at the naive behavior of many posters here. I was there until my father in-law's nephrologist friend brought me up to speed. The after hours trade was for $55 people!
Hey Martin...thanks for the update over at Aethlon. 5 could be a touch harsh..Rodell is just the better guy for the job right now. Joyce brought this a long way including the delivery to shareholders of Breakthrough Device status by the FDA. We talk about cancer treatment here, Joyce made it a reality at AEMD. Remember Ronco and Kellum likely remain on the scientific advisory board so their bench is strong to very strong here. Let's call a spade a spade shall we...CTSO is all alone in the #1 hole, but the horse on the rail is coming hard. Will likely see some news from June at some point advancing our cancer options. Exciting for all.
Aethlon, Spectral and Cytosorbent ..... can someone provide a quick pro and con on each of these filtration companys? Allow me to start and give my quick opinion ... I'll rank them with CTSO clearly in the #1 hole
1) CTSO = the leader with growing sales and the newest technology. The beads are very versatile and can treat almost anything. Great case studies but a little light in the loafers on randomized control trials and hard data on efficacy. REFRESH II should help, but like to see a 28 day mortality thrown into the secondary endpoint convo
2) EDTXF = Old technology and little in the way of sales. Perhaps the biggest stable of scientific backing and a complimentary diagnostic tool to help decide on treatment ...when, where and how much. Their product, Toraymyxin did receive a FDA compassionate care approval during their recently completed phase 3 trial here in the US. Likely need more trial work and waiting on an answer from the FDA. EDTXF trades OTC and does not share any company news through their trading symbol..a wait and sea story...don't buy the boat just yet
3) AEMD = perhaps the most interesting of the bunch with excellent insider backing and a niche product for infectious disease. Was an option during Ebola and could surprise with recent FDA fastrack designation. Perhaps worthy of the #2 hole, but the enormous usage on Spectral's Toraymyxin allows them to occupy the #2 hole ...for now.
Place your bets and have a super weekend
Anyone here from OrangeRob?
Thanks pal. I'm impressed with Chan's total...a real good sign for shareholders as he owns a solid 2% of the company. Hard to know how much he put in versus exercising of options, but 2% is nothing to sneeze at. Thanks for the reply and I now know where to find it.
NOBODY knows how much stock the CEO owns? You peeps shoudn't invest in bio stocks. Or do you know but think it wise not to say?
WOW Tech, excellent, what knowledge! So how does Fresenius position the product when they sell it to hospitals? What angle are they aproaching the market from? Is it for sepsis, cardiac, billirubin reduction, cancer treatment adjunctive? Has anyone seen the product listed on the Fresenius webpage? Curious how the 800 LB gorilla is positioning the filter.
What are CEO Chans total CTSO holdings?
Sounds very cool Martin. You do sound a touch naive though....bios take time and in our case the REFRESH II numbers will be awhile before they are available to us. Is it true that there is NO mortality benefit being considered in REFRESH II....not even as a secondary endpoint? I think you need mortality benefit to really make an impact as a medical device winner...maybe we add the mortality data as an extra data point later?? Anyone have an idea on this??
Thanks for the Chan trans feedback! So what is the total of CEO Chans CTSO holdings as of today? Thanks in advance
Did CEO Chan just sell 24,000 shares? If yes then why? What is the other part of the transaction? It shows a date of Monday. I thought these levels represented a good buying chance to average down. Has anyone talked to stock relations about the trade? Looks like the sell was in the mid $9 range
Just picked some up in the low 9.30s. Hope it was the right call to average down!
Chanie is fine a real trial is the problem. Our lack of a proper RCT or randomized control trial is the problem here is gaining real traction. Sure, I'm quite almost certain this product has rock-star efficacy, but the docs need the hard-core proof and that only comes by way of a solid RCT. Heed the call and do a large raise and let's get a solid septic trial on the books!
I hear ya brother and amen to that! I'm down large on my remaining 50% of this stock. I remain confident in the long term...regardless of how long that might be! Tough to talk $80 to $100 bones from $9, but would love to hear the path from any knowledgable holder. Long and strong on the Sorb!
Key $10 mark broken! Anyone on technicals or do you want more from the kidney doc? That son of a pup was right on with his call! Guess that is why he is a doc and the rest of us aren't!
Andy is KING! He responds to questions in 3 minutes! How does he do that and man oh man is he a smart (orange?) kitty! I agree about the usage thing, CTSO is ripe for the picking and YES of course you could use the same filter, there are something like 7 football fields worth of itsy bitsy grain of absorbent material in every filter...how cool is that! ?
What does the insider participation look like here? Please and thanks
Anyone know why we continue to drop?nother question is wht is the current insider position? My guess is they own a lot of it and tht is why it doesnt trade to much.
European sepsis study on 100 people less some. The study I was looking for has been brought to my attention by the kidney doc. He claims there was a study where more people died on our group, BUT the company said OUR group were a sicker lot of patients, something to do with kidney and dialysis patients, thus the nephrologist's interest.
I noticed Orangecat referred to pearsy as Paul. Does Orangecat know pearsy? WHY did Orange remove his own post?
I have been told that peasry was simply a creation to create an illusion that this was SO good that a basher would work tirelessly to try and pry stock from the frightened retailers sweaty palms?
Was pearsy just a created character for purposes of a message board story?
NO don't think that is the one. The primary endpoint is IL-6 reduction. I'm looking for the one that shows efficacy in 28 day mortality. How can we tout efficacy without a proper trial showing a reduction or perhaps an increase in 28 day mortality...it is all that really counts according to my father in-law's kidney doctor friend or nephrologist for those more medically inclined. Thanks though, the trial you posted didn't appear overwhelmingly worth discussing
Nice to have Cesare back and sharing stories from a public company rep sharing details on sales to stock traders
Removing posts inquiring about CTSO data appears a concern
Calling on a moderator for full explanation and efficacy results of the 100 person CTSO sepsis trial in Europe. My kidney doc contact would stop making me feel like a fool if I could provide him some real trial results that show how DANG good this American filter actually is!!!
Thanks Cars! CTSO DID run a real sepsis trial in Europe on 100 people a few years back. WHERE are the results of this? It would prove the efficaciousness of the filter PERIOD?
Cars...where are and what were the results?
1M is NO big deal...I can hardly get a nice house for 1M!!!
Cool Clints! so there comparing 20 people using the filter against a similar group of 16 others? Is that really a medically viable result to tout? I believe a much larger sepsis study was run in Europe several years ago. Could you please post the results of the study where placebo and Cytosorb were run on SAME study group? I think that to be more useful. Would you agree?